Recommendations for dose calculations of lung cancer treatment plans treated with stereotactic ablative body radiotherapy (SABR)

被引:2
|
作者
Devpura, S. [1 ]
Siddiqui, M. S. [1 ]
Chen, D. [1 ]
Liu, D. [1 ]
Li, H. [1 ]
Kumar, S. [1 ]
Gordon, J. [1 ]
Ajlouni, M. [1 ]
Movsas, B. [1 ]
Chetty, I. J. [1 ]
机构
[1] Henry Ford Hlth Syst, Detroit, MI 48202 USA
关键词
MONTE-CARLO; RADIATION-THERAPY; PHOTON BEAMS; ALGORITHM; VMC;
D O I
10.1088/1742-6596/489/1/012007
中图分类号
O59 [应用物理学];
学科分类号
摘要
The purpose of this study was to systematically evaluate dose distributions computed with 5 different dose algorithms for patients with lung cancers treated using stereotactic ablative body radiotherapy (SABR). Treatment plans for 133 lung cancer patients, initially computed with a 1D-pencil beam (equivalent-path-length, EPL-1D) algorithm, were recalculated with 4 other algorithms commissioned for treatment planning, including 3-D pencil-beam (EPL-3D), anisotropic analytical algorithm (AAA), collapsed cone convolution superposition (CCC), and Monte Carlo (MC). The plan prescription dose was 48 Gy in 4 fractions normalized to the 95% isodose line. Tumors were classified according to location: peripheral tumors surrounded by lung (lung-island, N=39), peripheral tumors attached to the rib-cage or chest wall (lung-wall, N=44), and centrally-located tumors (lung-central, N=50). Relative to the EPL-1D algorithm, PTV D95 and mean dose values computed with the other 4 algorithms were lowest for "lung-island" tumors with smallest field sizes (3-5 cm). On the other hand, the smallest differences were noted for lung-central tumors treated with largest field widths (7-10 cm). Amongst all locations, dose distribution differences were most strongly correlated with tumor size for lung-island tumors. For most cases, convolution/superposition and MC algorithms were in good agreement. Mean lung dose (MLD) values computed with the EPL-1D algorithm were highly correlated with that of the other algorithms (correlation coefficient =0.99). The MLD values were found to be similar to 10% lower for small lung-island tumors with the model-based (conv/superposition and MC) vs. the correction-based (pencil-beam) algorithms with the model-based algorithms predicting greater low dose spread within the lungs. This study suggests that pencil beam algorithms should be avoided for lung SABR planning. For the most challenging cases, small tumors surrounded entirely by lung tissue (lung-island type), a Monte-Carlo-based algorithm may be warranted.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] An audit on the outcomes of patients with primary lung cancer treated with stereotactic ablative radiotherapy (SABR) at a single institute between 2013 and 2018
    Mccabe, A.
    Foweraker, K.
    Pascoe, A.
    LUNG CANCER, 2019, 127 : S76 - S76
  • [42] The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)
    Moreno-Olmedo, Elena
    Sabharwal, Ami
    Das, Prantik
    Dallas, Nicola
    Ford, Daniel
    Perna, Carla
    Camilleri, Philip
    CANCERS, 2024, 16 (15)
  • [43] Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
    Ma, Ting Martin
    Lilleby, Oscar
    Lilleby, Wolfgang A.
    Kishan, Amar U.
    CANCERS, 2020, 12 (12) : 1 - 20
  • [44] Safety and efficacy of neoadjuvant stereotactic ablative radiotherapy (SABR) in pancreatic cancer
    Song, J. Y.
    Chie, E. K.
    Kim, Y.
    Ryu, J. K.
    Lee, S. H.
    Paik, W. H.
    Cho, I. R.
    Kim, H.
    Jang, J.
    Kang, H.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1105 - S1105
  • [45] Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer
    Lopez-Valcarcel, Marta
    Valcarcel, Francisco J.
    Velasco, Joaquin
    Zapata, Irma
    Rodriguez, Ruth
    Cardona, Jorge
    Gil, Beatriz
    Cordoba, Sofia
    Benlloch, Raquel
    Hernandez, Maria
    Santana, Sofia
    Gomez, Ricardo
    de la Fuente, Cristina
    Garcia-Berrocal, M. Isabel
    Regueiro, Carlos
    Romero, Jesus
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2024, 29 (04) : 445 - 453
  • [46] Is stereotactic ablative radiotherapy (SABR) a safe treatment for multiple primary lung cancer (MPLC) non-small cell lung cancer (NSCLC)?
    Murray, P. F.
    Spencer, K.
    Snee, M.
    Dickinson, P.
    Jain, P.
    Clarke, K.
    Franks, K.
    LUNG CANCER, 2016, 91 : S48 - S48
  • [47] Stereotactic ablative body radiotherapy (SABR) for NSCLC oligometastatic patients: feasibility and outcomes
    Campisi, M. C.
    Navarria, P.
    Ascolese, A. M.
    De Rose, F.
    Alloisio, M.
    Infante, M.
    Palumbo, V.
    Reggiori, G.
    Tomatis, S.
    Scorsetti, M.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S119 - S119
  • [48] Implementation of Stereotactic Ablative Body Radiotherapy (SABR) for Spinal Oligometatases: Initial Experiences
    Smyth, M.
    Williams, M.
    Jones, S.
    Woodley, O.
    Bryant, A.
    Matthams, C.
    Maloney, H.
    Millin, T.
    Palaniappan, N.
    Rackley, T.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E57 - E57
  • [49] Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases
    Siva, S.
    Bressel, M.
    Loi, S.
    Sandhu, S.
    Tran, B.
    Mooi, J.
    Lewin, J.
    Azad, A.
    Colyer, D.
    Shaw, M.
    Chander, S.
    Cuff, K.
    Wood, S.
    Lawrentschuk, N.
    Murphy, D.
    Pryor, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S248 - S248
  • [50] Efficacy and safety profile of Stereotactic Ablative Radiotherapy (SABR) for multiple lung primaries
    Littlejohns, A.
    Janjua, T.
    Murray, P.
    Jain, P.
    Clarke, K.
    Dickinson, P.
    Teo, M.
    Saha, A.
    Franks, K.
    Sun, F.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S542 - S542